Quantification and pharmacokinetics of astragaloside II in rats by rapid liquid chromatography-tandem mass spectrometry

Mean plasma concentration–time profiles of AST II determined by the LC-MS/MS method after intravenous and oral administration of AST II to rats. The oral absolute bioavailability (F) of AST II in rats was calculated to be 0.79 ± 0.16%, suggesting its poor absorption and/or strong metabolism in vivo.

Download Full-text

Simultaneous determination of 1,3-dicaffeoylquinic acid and caffeic acid in rat plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study

Analytical Methods ◽

10.1039/c4ay02968b ◽

2015 ◽

Vol 7 (8) ◽

pp. 3587-3592 ◽

Cited By ~ 5

Author(s):

Guoliang Dai ◽

Shitang Ma ◽

Bingting Sun ◽

Tao Gong ◽

Shijia Liu ◽

...

Keyword(s):

Mass Spectrometry ◽

Liquid Chromatography ◽

Plasma Concentration ◽

Rat Plasma ◽

Tandem Mass ◽

Concentration Time ◽

Chromatography Tandem Mass Spectrometry ◽

Dicaffeoylquinic Acid ◽

Liquid Chromatography Tandem Mass

The figure shows the average plasma concentration–time curves after an intravenous administration of 4 mL kg−1 Dengzhanxixin injection to rats.

Download Full-text

Bile Acids Quantification by Liquid Chromatography–Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study

Diagnostics ◽

10.3390/diagnostics10070462 ◽

2020 ◽

Vol 10 (7) ◽

pp. 462 ◽

Cited By ~ 2

Author(s):

Elisa Danese ◽

Davide Negrini ◽

Mairi Pucci ◽

Simone De Nitto ◽

Davide Ambrogi ◽

...

Keyword(s):

Mass Spectrometry ◽

Liquid Chromatography ◽

Healthy Subjects ◽

Reference Range ◽

Tandem Mass ◽

Chromatography Tandem Mass Spectrometry ◽

Liquid Chromatography Tandem Mass ◽

Interference Study

Bile acids (BA) play a pivotal role in cholesterol metabolism. Their blood concentration has also been proposed as new prognostic and diagnostic indicator of hepatobiliary, intestinal, and cardiovascular disease. Liquid chromatography tandem mass spectrometry (LC–MS/MS) currently represents the gold standard for analysis of BA profile in biological samples. We report here development and validation of a LC–MS/MS technique for simultaneously quantifying 15 BA species in serum samples. We also established a reference range for adult healthy subjects (n = 130) and performed a preliminary evaluation of in vitro and in vivo interference. The method displayed good linearity, with high regression coefficients (>0.99) over a range of 5 ng/mL (lower limit of quantification, LLOQ) and 5000 ng/mL for all analytes tested. The accuracies were between 85–115%. Both intra- and inter-assay imprecision was <10%. The recoveries ranged between 92–110%. Each of the tested BA species (assessed on three concentrations) were stable for 15 days at room temperature, 4 °C, and −20 °C. The in vitro study did not reveal any interference from triglycerides, bilirubin, or cell-free hemoglobin. The in vivo interference study showed that pools obtained from hyper-cholesterolemic patients and hyper-bilirubinemic patients due to post-hepatic jaundice for benign cholestasis, cholangiocarcinoma and pancreatic head tumors had clearly distinct patterns of BA concentrations compared with a pool obtained from samples of healthy subjects. In conclusion, this study proposes a new suitable candidate method for identification and quantitation of BA in biological samples and provides new insight into a number of variables that should be taken into account when investigating pathophysiological changes of BA in human diseases.

Download Full-text